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Background. Chemotherapy, radiotherapy, and surgery are routine treatments of breast cancer. However, these methods could only
improve the living survival. Nowadays the combined therapy including herbals such as crocin is to study for improving breast
cancer treatment. The purpose of this study was to evaluate the effects of crocin, paclitaxel, and radiation on MCF-7 cell.Methods.
To evaluate the effect of crocin, paclitaxel, and radiation on survival rate of MCF-7 cells MTT assay was done. To investigate the
apoptotic effect of experimental groups PI-flow cytometry was used and expression of apoptotic proteins (caspase-7, caspase-9,
PARP, and p53) was studied by western blot. Results.This study revealed that the combined therapy of 0.01𝜇mol/mL paclitaxel and
2.5 mg/mL crocin after 48 h could cause IC50 for MCF-7 cell line. This study showed that the combined therapy of 2Gy gamma
radiation with crocin could rise apoptosis in MCF-7 cell line from 21% (related to using 2Gy gamma radiation alone) to 46.6%.
Conclusion. Crocin and paclitaxel and crocin and gamma radiation had synergistic effect onMCF-7 cell line to get more significant
apoptosis.
1. Introduction
Breast cancer is the most common malignant neoplasm
among women in the world [1]. Due to globally uncontrolled
growth in recent years, it is very important. In United States
one of every eight women is facing this disease. Only in
2013 about 230,000 women and 2000 men were also added
to this cancer society [2]. Although the incidence of cancer
in Asia is low, its death toll is more than that in western
countries. In Iran, breast cancer has the highest incidence
among malignancies in women. It has been found that the
incidence of breast cancer in Iran is less than that in devel-
oped countries. However, this disease is the most common
cancer among the Iranian women. The incidence of this
malignancy has increased in the past two decades [3].
Radiotherapy, chemotherapy, and surgery are the com-
mon treatment methods for breast cancer. Mostly surgery
could not remove the tumor completely. Radiotherapy and
chemotherapy could damage healthy tissues too, so that
for considering healthy tissues tolerance radiation and drug
doses have to be kept at a limited level. Therefore, only the
living survival could be improved for a few years.
Saffron has various pharmacological effects. It could be
used to cure vomiting, dental and gingival pain, insomnia,
depression, seizures, cognitive disorders, diaphoretic, eupep-
tic, expectorant, and aphrodisiac and in the treatment of hep-
atic disorders, flatulence, spasm, asthma, coughs, bronchitis,
colds, fever, cardiovascular disorders, cancer, andmany other
diseases. Crocin is the carotenoid pigments creating the
redness of saffron [4]. Some studies reported the anticancer
effects of crocin [5–7]. Crocin is a phytochemical to kill
cancer cells without damaging the normal cells. Therefore, it
could be used in combination with chemotherapy drugs to
reduce the toxic effects of drugs [8].
Paclitaxel is a kind of the chemotherapy drugs. Because
of paclitaxel’s ability to bind to the beta tubulin subunit, it
increases the production of microtubules and prevents them
from depolymerization. This event consequently disrupts
the cell mitosis and stops cells in the G2 phase leading to
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apoptosis [9]. The most important adverse effect and dose-
limiting prescription of paclitaxel is the deactivation of the
hematopoietic system.This ismanifested by reduction of neu-
trophils (neutropenia), reduction of leukocytes (leukopenia),
and anemia [10]. Paclitaxel may cause some cardiovascular
complications such as low blood pressure (hypotension),
heart rate (bradycardia), and high blood pressure (hyperten-
sion) [11]. Nausea and vomiting are the other side effects of
paclitaxel [12, 13].
DNA is a critical target for ionizing radiation since it
includes information to encode biomolecules, so that its dam
-age such as single strand break (SSB), double strand break
(DSB), and dimerization could threat the cell viability
strongly [14, 15].
Therefore, the ionizing radiations have potential to induce
DNA damage and apoptosis [16].
The term of apoptosis was first established by Kerr in
1972 to describe the physiological cell death based on mor-
phological changes and tomake differentiation from necrosis
[17]. Apoptosis is a common type of cell death in eukaryotes.
This process is performed during embryonic stage and tumor
suppression [18].
According to increasing prevalence of breast cancer and
the adverse effects of treatment programs including resistance
to chemotherapy drug and damage to healthy tissues during
chemotherapy and radiotherapy, this study aimed to asses
synergistic apoptotic effect of crocin and paclitaxel and crocin
and gamma radiation, respectively, on MCF-7 cell line.
2. Materials and Methods
2.1. Cell Lines and Reagents. MCF-7 cell line, noninvasive
estrogen receptor (ER) positive, was prepared from the Pas-
teur Institute (Tehran, IRAN). Trypsin, crocin, 3-(4,5-dim-
ethylthiazol-2-yl)-2, 5-diphenyltetrazolium (MTT), and pro-
pidium iodide (PI) were purchased from Sigma (Germany).
Dulbecco’s Modified Eagle’s Medium (DMEM) high glu-
cose with 5% fetal bovine serum was purchased from
Gibco (USA). Paclitaxel was purchased from Sobhan Darou
(Tehran, Iran). Rabbit monoclonal antibody of caspase-7,
caspase-9, and PARP andmouse monoclonal antibody of p53
were prepared from Cell Signaling (USA).
2.2. Cell Culture and Research Methods. MCF-7 cells were
cultured in the DMEM high glucose medium with 10% heat-
inactivated fetal bovine serum, 100 units/mL penicillin, and
100mg/mL streptomycin and maintained in a humidified
atmosphere at 37∘C and 5% CO
2
. Cells in the logarithmic
growth period were selected for experimental studies.
2.3. Measurement of the Survival Rates of MCF-7 Cells with
MTT Method. 25000 cells were seeded in the 24-well plate
with 1mL of culture medium for 24 h. Different concen-
trations of 1.5mg/mL, 2.5mg/mL, 3.5mg/mL, 4.5mg/mL,
and 6mg/mL for the crocin and 0.01𝜇M/mL, 0.03𝜇M/mL,
0.05𝜇M/mL, 0.1𝜇M/mL, 0.5𝜇M/mL, and 1 𝜇M/mL for the
paclitaxel were examined separately to get IC50 (inhibition
concentration) for MCF-7 at the minimum possible time. On
this base the incubation times for crocin were used 24 h, 48 h,
and 72 h and for paclitaxel 48 h. Then the medium was being
removed and cells were incubated with 100 𝜇L (5mg/mL
dissolved in PBS) MTT and 900𝜇L medium culture at 37∘C
for 4 h. For each well the supernatant was discarded, 500𝜇L
DMSO was added, and the mixture was suspended.The light
absorbance (𝐴) was measured at 570 nm wavelength using
ELISA. Finally survival rate calculated as follows:
survival rate of tumor cells (%)
=
experimental group 𝐴 value
control group 𝐴 value
× 100%.
(1)
All above steps were done for crocin and paclitaxel separately.
As a result concentrations of 2.5mg/mL for crocin and
0.01 𝜇M/mL for doxorubicin were selected as the optimized
concentrations.
Then four groups of MCF-7 were selected to study
three methods of treatments as follows: control group, sec-
ond group irradiated by 2Gy gamma radiation (Cobalt 60
source), the third group which received 2.5mg/mL crocin
with 0.01𝜇M/mL paclitaxel, and finally the fourth group
which was studied by 2.5mg/mL crocin with 2Gy gamma
radiation for the combined group; meanwhile, we had several
control groups.
2.4. Determination of Cell Apoptosis by Flow Cytometry.
Apoptotic cells were revealed by the flow cytometry using PI
staining to detect the so-called sub-G1 peak [19]. For this
assay MCF-7 cells were cultured in a 6-well plate (70000
cells per well) and treated with 2.5mg/mL crocin for 24 h,
48 h, and 72 h. The second group of cells was treated with
0.01 𝜇M/mL of paclitaxel and the third group was irradiated
with 2Gy gamma. To evaluate the combined therapy, the
fourth group was treated by 2.5mg/mL crocin and 0.01 𝜇M/
mL paclitaxel for 48 h and the fifth group was treated by 2Gy
gamma and 2.5mg/mL crocin with 24 h incubation. Then
for all groups beside the control group the flow cytometry
analysis was being done.
2.5. Western Blot to Detect the Expression of Caspase-7 and
Caspase-9 and p53 and PARP of MCF-7 Cells. MCF-7 cell
lines were classified and treated similar to the two previous
methods. Then treated cells were detached by trypsinization,
washed with PBS, centrifuged in 4000 rpm for 5minutes, and
added to RIPA (lysis buffer). In the next step all samples were
put in ice for 30 minutes and vortexed every 5 minutes until
those would have been homogenizedwell.Then samples were
centrifuged 13000 rpm for 20minutes at 4∘C.The supernatant
was taken out and the concentration of protein was being
measured by Bradfordmethod. Protein samples were divided
into smaller amounts and kept at −80∘C.
To do western blot at first running buffer and transfer
bufferwere prepared and then three stepswere being followed
up: (a) proteinswere separated according tomolecular weight
by gel electrophoresis and (b) transferred to nitrocellulose
membrane and (c) the desired protein was specified with the
primary antibody and shown with the secondary antibody.
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(a) MTT assay with crocin mg/mL 24 hours
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(b) MTT assay with crocin 48 hours
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(c) MTT assay with crocin mg/mL 72 hours
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(d) MTT assay with paclitaxel 𝜇mol/mL 48 hours
Figure 1: Survival rate of Mcf-7 cells with different concentration of crocin in (a) 24 h, (b) 48 h, and (c) 72 h. (d) The survival rate of Mcf-7
cells with different concentration of paclitaxel in 48 h measured by MTT.
Finally antibody bonds appeared with ECL on the film. The
thickness of each bond was directly related to the amount of
protein.
3. Results
3.1. Changes of Survival Rates of MCF-7 Cells. MTT showed
crocin decreased cell viability ofMCF-7 cell line with increase
of dose and time. IC50 for this cell line was obtained with
3.5mg/mL crocin after 48 h treatment (𝑝 < 0.05) (Figure 1).
IC50 was measured for treatment with 0.1 𝜇m/mL paclitaxel
after 48 hours (𝑝 < 0.05) (Figure 1).
This study revealed that the combined therapy of
0.01 𝜇mol/mL paclitaxel and 2.5mg/mL crocin after 48 h
could cause IC50 for MCF-7 cell line (𝑝 < 0.05) (Figure 2).
This result was found by MTT assay. Also the combined
therapy of 2Gy gamma radiation with 2.5mg/mL crocin
revealed 50%cell death (𝑝 < 0.05) (Figure 3).Thatwas greater
than 22% cell death for using 2Gy radiations alone.
3.2. Apoptosis Changes of MCF-7 Cells. Flow cytometry with
PI is used to assess apoptosis. One of the main character-
istics of apoptotic cells is DNA fragmentation. Therefore,
nuclear DNA content of the cells is less than that in normal
cells. Nuclear-containing could be evaluated and specified in
hypodiploid cells by DNA binding fluorochromes such as PI
[20]. Apoptotic cell population is defined by SUBG1 peak.
This study revealed that treatment with 2.5mg/mL crocin
in 24, 48, and 72 hours could cause increase of apoptosis in
MCF-7 cell line with time (Figure 4). Also it was found that
4 International Journal of Breast Cancer
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Figure 2: Survival rate ofMcf-7 cells with different concentration of
crocin 2.5mg/mL and 0.01 𝜇m/mL of paclitaxel 48 h.
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Figure 3: Survival rate of Mcf-7 cells with 2Gy radiation 24 h and
combination of 2Gy radiation 24 h and crocin 2.5mg/mL 48 h.
the combined therapy of 2.5mg/mL crocin and 0.01 𝜇m/mL
paclitaxel could increase apoptosis significantly more than
that in the single therapy (𝑝 < 0.05) (Figure 4).
This study showed that the combined therapy of 2Gy
gamma radiation with crocin could raise apoptosis in MCF-
7 cell line from 21% (related to using 2Gy gamma radiation
alone) to 46.6% (𝑝 < 0.05) (Figure 4).
3.3. The Expression of Caspase-7 and Caspase-9, p53, and
PARP of MCF-7 Cells by Western Blot. Western blot test
showed combined therapy ofMCF-7 cell line with crocin and
paclitaxel or crocin and radiation could increase the expres-
sion of 4 proteins including caspase-7 and caspase-9, p53, and
PARP more than that in single therapy (𝑝 < 0.05) (Figure 5).
4. Discussion
As mentioned earlier, breast cancer is the most common
malignant neoplasm among women in the world. Despite
using the routine therapeutic approaches including surgery,
chemotherapy, and radiotherapy in patients with cancer,
their mortality remains high. It means that those therapeutic
modalities need to be modified. In addition, the destructive
effects of chemotherapy and radiation on normal cells are
other important concerns [11]. Nowadays trends have been
focused on natural products such as saffron with anticancer
properties to get the better treatment for cancer.
Chryssanthi et al. showed that constituents of saffron
(crocin, crocetin, and safranal) could stop the proliferation of
MCF-7 cell line [12]. Our study approved this antiproliferative
effect of crocin. Other scientists have approved this antipro-
liferative effect of crocin, saffron carotenoids pigment on
HEPG2 cell, and colorectal cancer cells with no harmful effect
on normal cells too [13–15]. Our study evaluated survival rate
of MCF-7 cells in treatment with paclitaxel, crocin, radiation
and used MTT assay. Our research showed that crocin could
inhibit the proliferation of MCF-7 cells in a dose and time
dependent manner. For example, when the concentration of
crocin increased from 1.5mg/mL to 6mg/mL in 48 h, the
survival rate of MCF-7 cells reduced from 75% to 23% and
the survival rate of MCF-7 cells reduced from 80% to 17%
in treatment of cells with paclitaxel from 0.01𝜇M/mL to
1 𝜇M/mL in 48 h. Paclitaxel reduced the survival rate in a
dose dependent manner. Similar to our results Hoshyar et al.
showed dose dependent and time dependent effect of crocin.
Sun et al. revealed the apoptotic effect of crocin onTca8113
[16]. Our study approved this effect on MCF-7 cell line. Li et
al. revealed the synergistic effect of crocin and cisplatin on
OS732, MG63 cells treatment. They showed the combination
of crocin and cisplatin to have the strong effect of killing and
suppressing of invasion cells, and it could be even more due
to the expression of caspases-8 and -3 [17]. The mechanism
of apoptosis is complex and based on a cascade of molecular
events. It depends on energy. There are generally 2 pathways
to induce apoptosis: extrinsic pathway and intrinsic pathway.
These two routes are interrelated. Also T lymphocyte induces
cytotoxic activity on the target cells [18]. It could be known as
the third way. Caspases cut the aspartate units. This process
activates the procaspases. Caspases in cascade activation
could activate another caspase through a chain reaction
strengthening and intensifying the route of apoptosis and
rapid cell death. These enzymes are in three groups: initiator
(caspases-2, -8, -9, and -10), broker (caspases-3, -6, and -7),
and inflammatory (caspases-1, -4, and -5) [19–21].
PUMA gene is directly induced by P53 in response to
DNA injury [22]. Expression of PUMA causes the release
of cytochrome c of mitochondria stimulating cell death [23,
24]. In the inner or mitochondrial pathway of apoptosis,
interaction of cytochrome c, Apaf-1, and procaspase-9 creates
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Figure 4: Measurement of apoptosis by PI flow cytometry: (a) control 48 h, (b) crocin 2.5mg/mL 24 h, (c) crocin 2.5mg/mL 48 h, (d) crocin
2.5mg/mL 72 h, (e) paclitaxel 0.01 𝜇m/mL, (f) crocin 2.5mg/mL + paclitaxel 0.01 𝜇m/mL, (g) radiation 2Gy 24 h, and (h) crocin 2.5mg/mL
48 h + radiation 2Gy 24 h.
apoptosome [25]. Apoptosome activates caspase-9 activating
executive caspases such as 3, 6, and 7 [26].
Cellular stresses such as DNA damage, radiation, or
chemical carcinogens activate p53. According to the type and
severity of toxicity, p53 could cause cell cycle arrest or cell
death due to apoptosis. The former allows DNA repair and
the latter causes cell loss [27, 28].
PARP as the cellular protein is cleaved specifically in
apoptosis. Particular proteolysis of PARP happens in the
DNA binding domain. Caspase-3 and caspase-7 are the most
effective proteases for PARP cleavage. As a result, PARP splits
into two 89 and 24 kDa subunits. These subunits are indica-
tive of apoptosis. Therefore, in this study PI flow cytometry
was used to evaluate MCF-7 cell line apoptosis and western
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Figure 5: (a) Western blot of cells treated by 2.5 and 4.5mg/mL of crocin, (b) western blot of cells treated by paclitaxel 0.01𝜇m/mL and
paclitaxel 0.01 𝜇m/mL + crocin 2.5mg/mL, and (c) western blot of 2Gy gamma radiation and 2Gy + crocin 2.5mg/mL.
blot was used to study the expression of proteins involved in
apoptosis [29].
Saunders et al. demonstrated apoptosis in MCF-7 cells
using 0–20 ng/mL paclitaxel. Our study evaluated the com-
bined therapy of paclitaxel-crocin and paclitaxel-radiation
for MCF-7 cell line and found the synergistic effect of those
methods. So that 2.5mg/mL crocin and 0.01 𝜇M/mL pacli-
taxel for 48 hours could cause 54.01% of cells in subG1
phase. This value for the combined therapy of 2.5mg/mL
crocin and 2Gy gamma radiation was obtained 46.6%. The
results showed that the expression of apoptotic proteins in the
combination groups was significantly higher than the single
groups [30].
5. Conclusion
The combined therapy of crocin and paclitaxel or crocin and
gamma radiation has synergistic effect for increasing apopto-
sis and survival rate reduction of MCF-7 cell line. Therefore,
it could be suggested to do more study for new breast cancer
treatment. In this combined therapy concentration of crocin,
drug, and treatment duration are the important factors to get
higher apoptosis and lower survival rate in MCF-7 cell line.
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